1.1Longer repeat segment
The structure sets n to 2 and retains the terminal attachment points of the indexed segment. The added repeat unit increases the number of backbone atoms along the path between those points.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The structure sets n to 2 and retains the terminal attachment points of the indexed segment. The added repeat unit increases the number of backbone atoms along the path between those points.
Hydrogen occupies each position and completes the valence at both attachment sites. The resulting structure has less substituent bulk at those sites than a structure with an alkyl group at either site.
An oxygen atom links the scaffold to the methyl group. The oxygen provides a hydrogen-bond acceptor and changes the polarity at R25.
The nitrile carbon attaches directly at R34. The cyano group withdraws electron density and supplies a dipole without a halogen at any of the five positions.
The vinyl group attaches through one of its double-bonded carbon atoms. The carbon–carbon double bond holds the two carbons in a planar geometry and restricts rotation between them.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A pharmaceutical manufacturing line uses the intracellular infection formulation as the test material during filling. An automated sampler diverts filled units from the beginning, middle and end of each run to a quality control station. Liquid chromatography measures active compound content, and a gravimetric station measures fill mass. The batch record links both measurements to the corresponding fill times.
An oral pharmaceutical composition uses doxycycline in place of the formula-defined active compound for treatment of a susceptible intracellular bacterial infection. A capsule contains doxycycline hyclate and microcrystalline cellulose in a dissolvable shell. After the capsule dissolves, absorbed doxycycline enters host cells and inhibits bacterial protein synthesis by binding to the bacterial 30S ribosomal subunit.
A paddle dissolution apparatus holds one oral dosage unit of the pharmaceutical composition per vessel. Separate runs use 500 mL and 900 mL of the same dissolution medium at 37 °C and a paddle speed of 50 revolutions per minute. Samples collected at 5, 15, 30 and 60 minutes pass through a filter before liquid chromatography. The measured concentrations and vessel volumes yield release profiles after correction for the active compound removed during sampling.
A microfluidic cell culture chip integrates a dosing reservoir, a perfusion pump and a chamber lined with uninfected mammalian cells. The pump delivers culture medium containing the active compound through the chamber and directs the outlet into timed collection tubes. A terminal rinse removes residual medium before the cells are lysed. Liquid chromatography coupled with mass spectrometry measures the active compound in both the outlet fractions and cell lysate.
A two-chamber dialysis apparatus pairs a donor chamber containing the pharmaceutical composition with a stirred receiver chamber containing buffer. A membrane separates the chambers and passes the dissolved active compound while retaining suspended formulation particles. A parallel donor chamber containing the active compound in solution measures the contribution of membrane transport to the observed release rate. Liquid chromatography measures the active compound in sequential receiver samples.
A liquid handler dispenses a concentration series of the active compound onto uninfected mammalian cells in a multiwell plate. The plate includes vehicle controls and cell-free wells for background measurement. An automated microscope images a nuclear stain and a membrane-impermeant viability dye in each well. Image analysis counts nuclei and calculates the fraction of dye-positive cells at each concentration after background correction.
R1 is ethyl and R2 is hydrogen. The ethyl group contains two carbons and attaches through its methylene carbon.
R3 is fluoro, R4 is methoxy, and R5 through R14 are hydrogen. Fluorine bonds directly at R3, and the methoxy group bonds through oxygen at R4.
R30 is methyl and R31 is cyclopropyl. The cyclopropyl group attaches through one carbon of its three-membered ring.
R61 is hydroxy, R62 is trifluoromethyl, and R63 and R64 are hydrogen. The hydroxy group attaches through oxygen, and the trifluoromethyl group attaches through the carbon bearing three fluorine atoms.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The compounds of the invention may be formulated into pharmaceutical compositions as natural or salt forms.A · US 7,179,834 B2 · ¶ 48
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substitA · US 7,179,834 B2 · ¶ 11
In a preferred aspect the invention relates to new isobenzoxazinones of formula (I) wherein R1 represents a long chain alkyl or isoalkyl substituent with CnH2n+1 and n=8-18, X represents —O— and R2, R3, R4 and R5 independently represent a substituent selected from hydrogen, fluorine, chlorine, bromine or C1-4 alkyl.B · US 2007/0219343 A1 · ¶ 22
In a preferred aspect the invention relates to new isobenzoxazinones of formula (I) wherein R1 represents a long chain alkyl or isoalkyl substituent with CnH2n+1 and n=8-18, X represents —O— and R2, R3, R4 and R5 independently represent a substituent selected from hydrogen, fluorine, chlorine, bromine or C1-4 alkyl.B · US 2007/0219343 A1 · ¶ 22
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substitA · US 7,179,834 B2 · ¶ 11
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substitA · US 7,179,834 B2 · ¶ 11
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substitA · US 7,179,834 B2 · ¶ 11
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substitA · US 7,179,834 B2 · ¶ 11
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substitA · US 7,179,834 B2 · ¶ 11
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substitA · US 7,179,834 B2 · ¶ 11
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substitA · US 7,179,834 B2 · ¶ 11
wherein: R1 to R3 are each independently —H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, —C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substitA · US 7,179,834 B2 · ¶ 11
An empty cell means only that no passage was reproduced there.
Thus, there is a continuing need for anti-neoplastic agents that are effective in inhibiting the proliferation of hyperproliferative cells while also exhibiting IC50 values lower than those values found for current anti-neoplastic agents, thereby resulting in marked decrease in potentially serious side effects.A · US 7,179,834 B2 · ¶ 8
The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.A · US 7,179,834 B2 · ¶ 9
The present invention relates to new isobenzoxazinones, in particular of formula (I), and their use as ultraviolet light absorbers for organic materials, in particular for organic polymers.B · US 2007/0219343 A1 · ¶ 1
UV absorbers help to prevent polymer degradation by reducing the harmful effects of ultraviolet rays by absorption through chromophores and by lowering the initiation rate through deactivation of excited states in the polymer matrix.B · US 2007/0219343 A1 · ¶ 5
patent.fyi, US 2026/0355213 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355213/, SHA-256 5fed1460f7de79c7edb1333521a4458fd21ad8348bbc5748c4c90b29630e18df